Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads scans to spot esophageal cancer and predicts best treatment path

NCT ID NCT07629921

Diagnosis Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 19, 2026 · Updated 5 times

Summary

This study tests two AI models that analyze endoscopy and CT images to diagnose esophageal cancer and predict how deep the tumor has grown. The goal is to help doctors decide if a patient can be treated with a less invasive endoscopic procedure or needs more aggressive therapy. The trial includes 264 participants with esophageal squamous cell carcinoma.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this AI tool could help doctors more accurately diagnose esophageal cancer and decide whether patients need surgery or less invasive treatment.
What could go wrong
This is an early-stage AI model study, not a treatment trial. The AI may not be accurate enough for all patients, and results may not apply to other hospitals or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

264 people

The number who actually took part.

Started

Mar 2023

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adult patients (≥18 years) with pathologically confirmed esophageal squamous cell carcinoma (ESCC) who underwent diagnostic endoscopy and contrast-enhanced CT examination at participating centers. Patients with early-stage disease who received endoscopic resection or esophagectomy and had pathological assessment of tumor invasion depth will be included for development and validation of a multimodal deep learning model for diagnosis and prediction of invasion depth. Patients with locally advanced disease who received neoadjuvant therapy followed by surgical resection, with available pathological response and follow-up data, will be included for development and validation of a multimodal model for predicting treatment response and prognosis. Clinical information, CT images, endoscopic images, pathological findings, and survival outcomes will be collected for analysis.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Histologically confirmed or clinically suspected esophageal squamous cell carcinoma (ESCC). * Availability of pre-treatment endoscopic images and contrast-enhanced chest/upper abdominal CT scans. * Availability of complete clinical and pathological data. * Patients who underwent endoscopic resection (ESD/EMR) or esophagectomy with pathological assessment of tumor invasion depth. * Adequate image quality for analysis. * Written informed consent (for prospective cohorts, if applicable). Exclusion Criteria: * Histology other than squamous cell carcinoma. * Prior treatment for esophageal cancer before baseline imaging, including chemotherapy, radiotherapy, immunotherapy, or endoscopic resection. * Distant metastatic disease at diagnosis. * Incomplete clinical, imaging, or pathological data. * Poor-quality CT or endoscopic images unsuitable for analysis. * History of another active malignancy within the past 5 years. * Recurrent esophageal cancer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal cancer

Contacts and locations

Locations

  • Zhongshan Hospital

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.